sever
viral
infect
includ
hemorrhag
fever
enceph
occur
throughout
world
preval
develop
area
vulner
infecti
diseas
also
infect
relat
speci
illustr
threaten
extinct
gorilla
ebola
infect
west
central
africa
safe
effect
treatment
avail
seriou
infect
addit
logist
difficulti
inher
develop
drug
infect
sporad
occur
mainli
third
world
overwhelm
barrier
hope
return
invest
encourag
pharmaceut
industri
address
unmet
medic
need
therefor
nation
institut
allergi
infecti
diseas
niaid
develop
support
varieti
program
resourc
provid
assist
lower
barrier
undertak
difficult
challeng
primari
program
relev
develop
therapi
sever
viral
infect
describ
three
case
studi
illustr
use
addit
contact
inform
access
resourc
suppli
publish
elsevi
bv
mani
reason
arsen
therapi
sever
viral
infect
includ
caus
highli
pathogen
rna
virus
exist
primari
reason
appli
develop
safe
effect
treatment
infect
caus
virus
sinc
virus
describ
oblig
intracellular
parasit
subvert
cellular
metabol
reproduct
process
persist
replic
difficulti
identifi
drug
target
would
derail
viral
correspond
author
tel
fax
email
address
claughlin
niaidnihgov
c
laughlin
replic
without
caus
concurr
host
toxic
easili
appreci
fact
idea
identif
safe
effect
antivir
drug
definit
imposs
scientif
dogma
mani
year
mistaken
ideolog
first
brought
question
discoveri
develop
amantadin
influenza
acyclovir
treatment
herp
simplex
final
laid
rest
emerg
hiv
aid
epidem
astonishingli
rapid
accomplish
develop
drug
five
separ
hiv
viral
target
howev
question
remain
similar
success
enjoy
rna
virus
caus
highli
pathogen
infect
unfortun
mani
reason
clear
difficult
solv
first
mani
virus
endem
emerg
sporad
part
world
inadequ
public
health
resourc
circumst
usual
correl
lack
econom
incent
pharmaceut
industri
secondli
mani
diseas
caus
rare
complic
clinic
evalu
potenti
therapi
importantli
mani
infect
caus
high
morbid
andor
mortal
therefor
research
requir
access
highlevel
biolog
contain
final
host
respons
infect
may
make
signific
contribut
patholog
antivir
monotherapi
may
suffici
diseas
control
sinc
infect
seriou
global
impact
natur
emerg
infect
also
potenti
misus
bioterrorist
us
govern
other
develop
publicli
avail
resourc
facilit
discoveri
develop
therapi
infect
articl
describ
mani
support
nation
institut
allergi
infecti
diseas
niaid
run
gamut
chemic
synthesi
limit
clinic
evalu
contact
inform
variou
program
provid
intellectu
properti
issu
discuss
articl
end
sever
exampl
specif
resourc
access
drug
develop
provid
data
fill
gap
develop
plan
therapi
antivir
test
program
niaid
support
vitro
screen
system
anim
model
human
viral
infect
assess
efficaci
toxic
potenti
therapeut
import
human
viral
infect
main
object
program
facilit
identif
antivir
agent
potenti
treatment
viral
infect
public
health
import
includ
newli
emerg
infect
low
prioriti
pharmaceut
industri
servic
free
supplier
interest
submit
compound
evalu
antivir
activ
gener
compound
put
vitro
evalu
prior
consider
evalu
relev
anim
model
niaid
encourag
academ
industri
investig
take
advantag
program
sinc
primari
purpos
program
encourag
success
product
develop
niaid
ensur
compound
supplier
intellectu
properti
right
protect
properli
execut
screen
agreement
requir
vitro
vivo
evalu
program
primari
purpos
agreement
assur
niaid
use
suppli
compound
clearli
defin
protect
right
supplier
niaid
develop
templat
agreement
modifi
assent
lawyer
niaid
supplier
vitro
screen
program
initi
design
examin
pure
compound
rare
occas
also
examin
biolog
extract
compel
rational
due
limit
resourc
niaid
support
fraction
extract
supplier
must
demonstr
capabl
fraction
extract
accept
program
although
except
occasion
made
chemic
ident
character
compound
screen
must
releas
niaid
staff
manag
keep
inform
confidenti
necessari
compound
screen
repeatedli
assay
replic
base
assay
influenza
sar
also
avail
high
throughput
format
virus
avail
screen
program
compound
sponsor
gener
receiv
data
back
within
month
inform
provid
sponsor
data
sheet
includ
median
effect
concentr
concentr
reduc
cell
viabil
posit
neg
control
alway
run
parallel
inform
submiss
inform
found
http
niaidaacforg
niaid
also
offer
antivir
evalu
servic
use
number
small
anim
model
human
viral
diseas
model
current
includ
mous
andor
hamster
model
biodefenserel
virus
punta
toro
pichind
yellow
fever
west
nile
influenza
includ
avian
venezuelan
western
equin
enceph
virus
biodefenserel
viral
model
serv
surrog
hazard
counterpart
punta
toro
surrog
rift
valley
fever
pichind
surrog
lassa
fever
program
also
includ
less
exot
pathogen
mous
model
herpesvirus
mous
rabbit
model
papillomaviru
cotton
rat
model
paramyxovirus
mous
model
orthopoxvirus
addit
program
offer
transgen
mous
model
hamsterscrapi
see
detail
descript
model
websit
referenc
niaid
contract
laboratori
staf
establish
investig
possess
strong
antivir
research
background
public
record
respect
anim
model
often
sever
differ
model
avail
individu
pathogen
may
vari
method
viru
inocul
anim
mortal
also
often
possibl
evalu
differ
method
drug
deliveri
appropri
intraperiton
topic
oral
intraven
well
rang
dose
regimen
first
experi
seri
usual
design
give
drug
everi
advantag
show
efficaci
candid
therapi
may
administ
time
viru
inocul
even
endpoint
includ
clinic
paramet
mortal
weight
oxygen
satur
laboratori
valu
viru
titer
variou
organ
therapeut
combin
also
evalu
model
tabl
list
select
current
avail
model
antivir
evalu
filovirus
current
offer
may
done
collabor
depart
defens
academ
investig
gain
access
test
servic
submitt
must
complet
vivo
test
submiss
form
provid
niaid
background
inform
product
submit
inform
use
niaid
staff
select
priorit
materi
test
criteria
priorit
includ
address
unmet
medic
need
novel
chemic
desir
pharmacokinet
characterist
util
novel
therapeut
strategi
pharmaceut
back
develop
often
materi
submit
vivo
test
program
hit
vitro
screen
process
except
includ
product
antiinflammatori
immunomodulatori
natur
product
would
expect
manifest
antivir
activ
vitro
product
consid
niaid
direct
submiss
anim
model
program
product
select
test
compound
sponsor
niaid
contractor
niaid
program
staff
work
togeth
develop
specif
protocol
evalu
product
experi
conduct
stepwis
fashion
continu
involv
three
parti
rare
sponsor
want
involv
plan
specif
studi
case
niaid
staff
anim
model
contractor
develop
plan
discuss
result
sponsor
although
capabl
chemic
assay
animalderiv
specimen
presenc
product
andor
metabolit
cover
contract
anim
model
contractor
harvest
tissueblood
sampl
appropri
time
compound
sponsor
arrang
assay
done
elsewher
collect
pharmacokinet
pharmacodynam
data
niaid
strongli
support
public
signific
find
made
auspic
niaid
antivir
test
program
although
public
may
delay
patent
protect
process
still
progress
inform
found
http
niaidaacforganimalshtm
tabl
mouseguinea
pig
bernstein
harrison
bernstein
et
al
bernstein
et
al
bourn
et
al
milligan
bernstein
quenel
et
al
stanberri
et
al
mous
human
cytomegaloviru
scidscidhuretscidhuthyliv
bravo
et
al
kern
et
al
guinea
pig
cytomegaloviru
normal
immunocompromis
newborn
pregnant
guinea
pig
bourn
et
al
bravo
et
al
mous
quenel
et
al
b
smee
et
al
smee
et
al
b
cowpox
mous
quenel
et
al
quenel
et
al
quenel
et
al
b
ectromelia
mous
parker
et
al
schriewer
et
al
christensen
et
al
christensen
et
al
rabbit
oral
papillomaviru
new
zealand
white
rabbit
christensen
human
papillomaviru
secondari
test
human
hffscid
mous
bonnez
iyer
et
al
hamster
scrapi
transgen
mous
kocisko
et
al
niaid
model
avail
free
charg
investig
whose
product
accept
program
refer
includ
provid
inform
model
provid
exampl
model
use
niaid
process
construct
two
contain
facil
continent
unit
state
two
part
alreadi
establish
govern
facil
capabl
laboratori
access
qualifi
investig
institut
although
specif
plan
manag
access
determin
prioriti
final
novemb
articl
prepar
sponsor
drug
whose
develop
would
requir
use
facil
contact
niaid
program
offic
tabl
avail
anoth
dmid
resourc
biodefens
emerg
infect
research
resourc
repositori
beir
resourc
provid
uniqu
qualityassur
biodefens
emerg
infect
reagent
resourc
scientif
commun
mission
beir
acquir
authent
produceexpand
preserv
distribut
niaid
categori
b
c
research
refer
reagent
investig
basic
research
product
improv
diagnost
test
vaccin
therapi
exampl
reagent
avail
beir
bacteria
protist
rickettsia
virus
fungi
cell
line
toxin
recombin
protein
synthet
peptid
monoclon
polyclon
antibodi
scm
nucleic
acid
genom
materi
clone
gene
reagent
avail
free
charg
regist
investig
acquisit
reagent
one
critic
necessari
challeng
task
beir
therefor
investig
highli
encourag
deposit
reagent
beir
provid
accessus
materi
relief
burden
distribut
reagent
provid
secur
storag
valuabl
reagent
addit
beir
capabl
contract
prepar
specif
reagent
reagent
need
advanc
specif
research
area
contact
niaid
program
offic
use
contact
option
beir
homepag
view
catalog
pleas
visit
http
wwwbeiresourcesorg
fund
opportun
avail
niaid
pleas
visit
http
wwwniaidnihgovncnbudgetdefaulthtm
despit
success
vitro
anim
model
program
identifi
compound
therapeut
potenti
clear
mani
promis
compound
achiev
development
potenti
mani
sponsor
lack
resourc
support
full
development
path
therefor
niaid
establish
comprehens
resourc
provid
array
servic
support
preclin
develop
therapeut
agent
identifi
niaid
fund
grant
contract
academia
privat
sector
sourc
select
niaid
program
staff
niaid
research
contract
known
servic
preclin
develop
therapeut
agent
offer
collect
preclin
servic
synthesisresynthesi
medicin
chemistri
formul
manufactur
packag
well
vivo
safeti
pharmacolog
toxicolog
studi
requir
support
clinic
use
human
indndabla
file
work
togeth
compound
sponsor
niaid
contract
product
develop
niaid
staff
also
provid
specif
preclin
product
develop
plan
evalu
exist
product
develop
plan
servic
offer
intend
fill
specif
gap
overal
develop
product
exampl
type
servic
provid
typic
small
molecul
therapeut
includ
compound
synthesi
formul
manufactur
dose
rang
find
rodentsnonrod
rat
pk
toxicolog
dog
pk
toxicolog
absorpt
distribut
metabol
excret
adm
howev
sophist
toxicolog
studi
also
avail
genotox
reproduct
toxicolog
studi
may
entail
special
capabl
investig
may
benefit
synthesi
candid
drug
drug
analog
quantiti
suffici
subsequ
biolog
biochem
analys
includ
radiolabel
compound
addit
investig
structur
lead
seri
compound
exhibit
efficaci
may
use
contract
pursu
lead
optim
develop
servic
involv
gener
lead
optim
scheme
gener
chemic
analogu
use
silico
system
predict
adm
preclin
product
develop
plan
evalu
servic
found
extrem
benefici
investig
new
product
develop
unfamiliar
regulatori
requir
need
fulfil
progress
ind
nda
bla
investig
lead
compound
understand
desir
indic
also
request
prepar
specif
development
plan
product
process
requir
investig
present
overview
studi
perform
disclos
exist
data
use
inform
contractor
develop
overal
preclin
product
develop
plan
specifi
therapeut
report
includ
brief
descript
studi
need
begin
phase
clinic
studi
list
go
nogo
decis
point
indic
interact
fda
take
place
estim
cost
step
servic
prove
use
mani
program
regardless
stage
drug
develop
process
specif
servic
request
depend
statu
individu
candid
part
overal
product
develop
plan
andor
regulatori
submiss
plan
fda
administr
procedur
request
servic
first
contact
niaid
program
offic
respons
specif
programmat
area
list
provid
tabl
investig
work
niaid
program
offic
identifi
studi
aid
drug
program
reach
stage
preind
meet
fda
competit
altern
fund
fulfil
fda
requir
nda
bla
enabl
studi
request
consid
basi
niaid
prioriti
technic
feasibl
avail
fund
although
research
frequent
abl
obtain
suffici
fund
vitro
anim
efficaci
studi
preclin
test
new
compound
support
may
avail
expens
clinic
trial
niaid
process
advertis
clinic
trial
unit
perform
phase
clinic
trial
prioriti
compound
whose
sponsor
financi
support
studi
budget
permit
award
may
made
contact
niaid
program
offic
inform
niaid
program
person
may
also
know
option
acquir
resourc
clinic
test
current
list
niaid
program
offic
virolog
program
provid
tabl
niaid
experi
provid
materi
may
hesit
submit
proprietari
product
program
risk
govern
contractor
may
obtain
right
invent
relat
provid
materi
therefor
niaid
procedur
place
help
assur
provid
right
compromis
submit
materi
evalu
develop
provis
incorpor
contract
niaid
hold
servic
provid
other
form
separ
agreement
niaid
contractor
niaid
investig
servic
contract
involv
use
third
parti
proprietari
materi
niaid
either
place
process
pursu
determin
except
circumst
dec
dec
requir
contractor
subcontractor
assign
right
bayhdol
act
subject
invent
use
incorpor
submit
materi
niaid
provid
design
niaid
otherwis
dispos
transfer
right
direct
niaid
contract
dec
yet
effect
intellectu
properti
ip
option
incorpor
contract
ip
option
offer
provid
option
negoti
exclus
licens
niaid
contractor
invent
use
provid
materi
includ
invent
either
conceiv
first
actual
reduc
practic
contractor
perform
work
done
contract
use
provid
materi
anoth
concern
amongst
third
parti
provid
confidenti
data
inform
provid
owner
materi
sever
procedur
place
protect
confidenti
proprietari
inform
gener
standard
niaid
contract
includ
claus
state
data
inform
provid
third
parti
supplier
niaid
project
offic
mark
confidenti
treat
confidenti
unless
specif
identifi
nonconfidenti
write
niaid
project
offic
last
niaid
would
prevent
submitt
directli
negoti
separ
term
condit
contractor
long
term
conflict
prenegoti
contract
niaid
place
contractor
intent
variou
provis
describ
protect
intellectu
properti
proprietari
right
provid
dmid
program
offic
avail
discuss
procedur
implement
contract
address
concern
although
centuri
bare
begun
first
year
alreadi
wit
emerg
spread
west
nile
viru
unit
state
sudden
emerg
sarsassoci
coronaviru
asia
threat
potenti
global
influenza
pandem
caus
highli
pathogen
avian
influenza
viru
moreov
unthink
threat
bioterror
face
societi
today
respons
emerg
public
health
issu
niaid
preclin
program
abl
rapidli
establish
antivir
assay
anim
model
respons
barnard
et
al
morrey
et
al
noah
et
al
severson
et
al
smee
et
al
adjust
use
resourc
address
new
need
although
two
resourc
describ
exist
year
mani
model
relev
biodefens
new
well
exampl
resourc
use
may
help
reader
understand
niaid
assist
compani
attempt
develop
new
drug
sever
viral
infect
addit
exampl
niaid
assist
develop
novel
therapi
poxviru
infect
recent
describ
bolken
hrubi
juvari
biotherapeut
small
compani
enrol
niaid
antivir
screen
program
juli
compani
develop
immunotherapeut
vaccin
product
treatment
prevent
human
diseas
compani
collabor
shown
cation
lipiddna
complex
cldc
abl
activ
innat
adapt
immun
respons
particular
induct
therapeut
quantiti
cytokin
well
humor
cellmedi
immun
follow
parenter
mucos
administr
initi
breadth
data
compani
develop
use
cldc
technolog
focus
treatment
cancer
anim
model
dog
natur
occur
tumor
dow
et
al
kamstock
et
al
uren
et
al
upon
entri
screen
program
jointli
decid
among
compani
senior
scientist
utah
state
univers
anim
model
contract
program
offic
test
protect
effect
cldc
treatment
punta
toro
viru
infect
murin
model
initi
studi
laboratori
dr
brian
gowen
utah
state
demonstr
protect
punta
toro
viru
infect
cldc
administ
either
prophylact
therapeut
gowen
et
al
result
studi
result
public
began
chang
juvari
corpor
strategi
manag
team
began
focu
effort
immunotherapeut
treatment
applic
infecti
diseas
combin
diseasespecif
antigen
cldc
produc
vaccin
capabl
activ
robust
antibodi
tcell
respons
herp
simplex
studi
conduct
contract
cincinnati
children
hospit
medic
center
laboratori
dr
david
bernstein
dr
rhonda
cardin
mice
immun
cldc
combin
enrich
glycoprotein
lysat
recombin
protein
shown
signific
reduct
viral
load
erythema
well
significantli
increas
surviv
manuscript
prepar
juvari
biotherapeut
current
evalu
clinic
develop
strategi
therapeut
prophylact
vaccin
result
success
outcom
studi
involv
niaidsponsor
program
compani
use
data
gener
niaid
antivir
screen
program
support
multipl
success
applic
financi
back
government
nongovernment
entiti
addit
niaidjuvari
collabor
studi
gener
substanti
interest
major
pharmaceut
group
macrogen
inc
enlist
niaid
antivir
test
program
june
submiss
human
west
nile
virusneutr
antibodi
niaid
contract
utah
state
univers
dr
john
morrey
colleagu
discov
could
significantli
protect
hamster
lethal
challeng
west
nile
viru
even
antibodi
administ
intraperiton
day
postvir
inject
timepoint
viru
alreadi
infect
neuron
brain
howev
timewindow
limit
therapeut
efficaci
model
work
collabor
establish
wnv
undergo
retrograd
axon
transport
prevent
paralysi
administ
day
intrasciat
nerv
inject
samuel
et
al
preclin
data
obtain
niaid
antivir
test
program
incorpor
propos
compani
submit
niaid
contract
program
provid
support
compani
undergo
later
stage
product
develop
septemb
macrogen
award
contract
program
develop
monoclon
antibodi
includ
manufactur
phase
clinic
trial
preclin
data
obtain
niaid
antivir
test
program
includ
ind
submit
fda
may
juli
compani
announc
ind
antibodi
activ
phase
clinic
trial
human
west
nile
virusneutr
monoclon
antibodi
began
august
toyama
chemic
compani
regist
niaid
antivir
test
program
januari
submit
pyrazin
deriv
report
initi
furuta
cowork
toyama
chemic
co
activ
influenza
virus
furuta
et
al
takahashi
et
al
collabor
compani
test
program
demonstr
activ
virus
panel
bunyavirus
arenavirus
gowen
et
al
complet
number
vitro
studi
vivo
test
toyama
lead
compound
perform
mous
model
influenza
contract
laboratori
utah
state
univers
principl
investig
time
dr
robert
sidwel
colleagu
discov
first
time
highli
activ
mice
lethal
infect
influenza
administ
per
os
postviru
exposur
twice
four
time
daili
dosag
mgkgday
well
toler
prevent
death
lessen
declin
arteri
oxygen
satur
inhibit
lung
consolid
lung
viru
titer
four
time
per
day
treatment
mgkgday
also
found
efficaci
treatment
delay
h
viru
exposur
remark
singl
treatment
administ
h
viru
exposur
prevent
death
arteri
oxygen
satur
declin
altogeth
experi
conduct
toyama
chemic
compani
versu
influenza
mous
model
preclin
efficaci
data
experi
use
support
toyama
ind
submiss
japan
unit
state
safeti
evalu
human
began
japan
januari
us
shortli
thereaft
niaid
continu
support
investig
combin
antivir
combin
substanc
may
effect
immun
modul
inflamm
addit
recent
work
niaid
contract
utah
state
univers
shown
activ
rodent
model
virus
influenza
suggest
may
broadspectrum
activ
rang
pathogen
rna
virus
gowen
et
al
nih
niaid
mission
involv
support
conduct
research
improv
public
health
global
well
domest
combin
recognit
potenti
impact
emerg
infect
lack
return
invest
need
pharmaceut
drug
develop
niaid
initi
program
tri
fill
gap
develop
therapi
potenti
medic
signific
relev
current
program
describ
howev
program
new
constantli
reevalu
addit
delet
made
deem
appropri
therefor
best
cours
action
address
development
need
therapi
sever
viral
infect
well
infecti
pathogen
contact
niaid
program
person
discuss
resourc
avail
might
best
appli
specif
development
challeng
